Objective. To investigate the roles of the synovial lymphatic system in the severity and progression of joint tissue damage and functional responses of synovial lymphatic endothelial cells (LECs) to macrophage subsets, and to evaluate the therapeutic potential of the proteasome inhibitor bortezomib (BTZ) in a mouse model of experimental posttraumatic osteoarthritis (OA).
INTRODUCTION
Osteoarthritis (OA) is characterized by the degeneration of articular cartilage, subchondral bone sclerosis, angiogenesis, and synovitis. Increasing evidence indicates that not only cartilage, but also surrounding soft tissues (referred to as synovium in this study) contribute to the pathogenesis of OA. Catabolic factors, including proinflammatory cytokines, immune cells, and proteases, are detected in OA synovium and play a critical role in cartilage degeneration (1, 2) 
. Mechanisms or pathways by which
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these factors are removed from the OA synovium have not been well studied.
The lymphatic system plays an important role in maintaining metabolic and tissue fluid homoeostasis. Interstitial fluid, immune cells, proteins, and lipids are drained by lymphatic capillaries from the interstitial space. They are then transported to lymph nodes, to the thoracic duct, and finally to the bloodstream via collecting lymphatic vessels (3) . Lymphatic capillaries are composed of a thin layer of lymphatic endothelial cells (LECs). The collecting lymphatic vessels are covered by 1 or more layers of lymphatic muscle cells that enable vessel contraction, moving the lymph against gravity (4) . We previously reported that the mouse knee contains a synovial lymphatic system that drains into the iliac lymph nodes, as demonstrated using an intraarticular (IA)-injected near-infrared (NIR) dye. This synovial lymphatic drainage is reduced in joints with meniscal ligamentous injury (MLI)-induced posttraumatic OA, a mouse model of experimental OA (5) . However, it is not known if reduced synovial lymphatic drainage is a consequence of posttraumatic knee OA or precedes the development of posttraumatic knee OA.
The function of lymphatic vessels is affected differently according to the duration of inflammation (6) . Increased lymphangiogenesis, lymphatic vessel contraction, and lymph flow occur in areas with acute inflammation. In contrast, reduced lymphatic vessel contraction and lymph flow occur in areas with chronic inflammation. This may be related to the high levels of inducible nitric oxide synthase (iNOS) produced by macrophages and LECs. Inducible NOS directly affects lymphatic muscle cells via excess nitric oxide (7, 8) . We observed that in mice carrying the tumor necrosis factor transgene (TNF-Tg), a model of rheumatoid arthritis (RA), macrophages were attached to LECs in the collecting lymphatic vessel that drains the inflamed joints (9) . However, whether macrophages affect LEC function directly remains to be determined. Effective lymphatic drainage promotes the resolution of inflammation.
Macrophages are plastic cells. Quiescent macrophages respond to different stimuli in vitro and will polarize to subsets of M1 (proinflammatory) and M2 (antiinflammatory) macrophages at opposite ends of the macrophage phenotype spectrum. M1 and M2 macrophages have distinct gene expression profiles (10) . M2 macrophages promote tumor lymphangiogenesis by producing vascular endothelial growth factor C (VEGF-C), the growth factor for LECs (11) . Synovium of OA patients contains both M1 and M2 macrophages (12) , but the role of these distinct macrophage populations in the lymphatic system under non-tumor conditions, such as in knee OA, has not been studied.
Bortezomib (BTZ) is a proteasome inhibitor that is approved by the US Food and Drug Adminisration for the treatment of patients with multiple myeloma (13) . BTZ inhibits proinflammatory cytokines in the T cells of RA patients (14) , and inhibits joint inflammation and bone erosion in mice with adjuvant-induced RA (15) . It suppresses TNF-induced type II collagen degradation and expression of matrix metalloproteinase 13 (MMP-13) in human chondrocytes (16) . MG132, a proteasome inhibitor that is used in biologic research, was found to reduce cartilage loss when applied in a prevention protocol in experimental animal models of surgery-induced OA (17, 18) . However, whether proteasome inhibition has a therapeutic role in OA or whether it can be associated with improvement of synovial lymphatics is unknown.
In the present study, we hypothesized that the progression of posttraumatic knee OA is associated with lymphatic vessel inflammation that is induced by M1 macrophages. This leads to reduced synovial lymphatic drainage and facilitates joint tissue damage, which can be attenuated by intraarticular administration of BTZ. We predicted that 1) blocking lymphatic function will accelerate OA tissue damage, 2) OA synovial LECs will express high levels of inflammatory genes, 3) OA synovium will have increased numbers of M1 macrophages, and M1 macrophages will affect LEC function, and 4) treatment with BTZ will reduce tissue damage, attenuate LEC inflammation, and improve synovial lymphatic drainage. In this study, we used a mouse model of MLI-induced posttraumatic knee OA and demonstrated an association among M1 macrophage activity, LEC inflammation, and synovial lymphatic drainage in the OA joints. Our findings also demonstrated the therapeutic potential of BTZ in this posttraumatic knee OA model.
MATERIALS AND METHODS
Experimental mouse model of posttraumatic knee OA. Three-month-old male C57BL/6J mice were subjected to MLI surgery to induce posttraumatic knee OA, which was carried out in accordance with a standard operation procedure established by the Center for Musculoskeletal Research (CMSR) in Rochester, New York (5, 19) . Briefly, a 5-mm incision was made on the medial aspect of the right joint, and the medial collateral ligament was transected to open the joint space. The medial meniscus was detached from its anterior attachment to the tibia, and the anterior half of the detached medial meniscus was removed. In sham surgery, a 5-mm skin incision was made on the medial aspect of the left joint. Mice received sustained-release buprenorphine to control pain.
Two experiments were conducted. In the first experiment, a VEGFR-3 neutralizing antibody (mF4-31C1; ImClone) was used. Mice with MLI-induced posttraumatic knee OA were treated with the VEGFR-3 antibody (at 0.8 mg/kg by intraperitoneal [IP] injection) or with IgG, starting at day 3 postsurgery, 3 times per week for 6 weeks, based on a regimen previously used in TNFTg mice (20) . In the second experiment, mice with MLI-induced posttraumatic knee OA were subjected to ultrasound imaging at 4 weeks postsurgery to obtain synovial volume (21, 22) . Based on their synovial volume values, the mice were randomized into 1 of 2 treatment groups: BTZ (0.25 mg/ml in a 5-μl IA injection) or vehicle control (1% DMSO) weekly for 7 weeks. All animal experiments were approved by the Animal Care and Use Committee at the University of Rochester.
NIR-indocyanine green (ICG) lymphatic imaging.
NIR-ICG imaging was performed by administering an IA injection of 5 μl (0.1 μg/μl) of ICG (Akorn) into the mouse knee joints, in accordance with the CMSR standard operating procedure (5, 23, 24) . The dynamics of ICG fluorescence over the entire leg were visualized using an NIR imaging system. Briefly, the target area was excited with NIR illumination provided by a tungsten halogen nondichroic MR16 light bulb. A fluorescence emission filter was placed behind the lens and in front of a high-sensitivity 1.4-megapixel CCD camera sensor. The camera, NIR excitation, and background illumination were controlled using software developed in the LabView programming environment.
Synovial lymphatic drainage, as indicated by the percentage of ICG clearance, was assessed by calculating the percentage difference of ICG signal intensity between the 3-and 6-hour NIR scans from the regions of interest in the knee joint after ICG injection (24) .
Histology and staining. Decalcified knee samples were used. For paraffin sectioning, 30 consecutive 4-μm-thick sections of the knee tissue were collected and evenly divided into 3 levels. One section from each of the 3 levels was stained with Alcian blue-hematoxylin-orange G. For frozen sectioning, 10 consecutive 7-μm-thick sections were collected. Sections 4 and 5 were stained with hematoxylin and eosin. An adjacent section was subjected to double immunofluorescence staining for lymphatic vessels and macrophage subsets using primary antibodies, including antibodies to podoplanin (PDPN) (1:200; Abcam) for LECs, F4/80 (1:50; BioLegend) for pan-macrophages, iNOS (1:50; Santa Cruz Biotechnology) for M1 macrophages, or CD206 (1:100; R&D Systems) for M2 macrophages. Stained sections were scanned with an Olympus VS120 whole-slide imager (5) .
For 3-dimensional (3-D) reconstruction, one 30-μm-thick frozen section of the synovial tissue was stained with anti-F4/80, anti-iNOS, and anti-PDPN antibodies, while another 30-μm-thick frozen section was stained with anti-F4/80, anti-CD206, and anti-PDPN antibodies, followed by scanning with an Olympus FV1000 confocal microscope to collect a series of 20-25 images. Images were imported to Amira software (version 6.0) for 3-D reconstruction.
Histomorphometric analyses. Joint tissue damage was assessed on Alcian blue-orange G-stained sections using the CMSR standard operating procedure. Histomorphometric assessments of joint tissue damage included the modified Osteoarthritis Research International (OARSI) score for histopathologic assessment of murine cartilage (25) , a score for the severity of synovitis (26) , and determination of osteophyte numbers (5, 19) . Three sagittal joint sections from 3 levels were used for these assessments, carried out in a blinded manner by 4 independent observers. The mean score for the 3 levels from each observer was calculated, and the mean score from all 4 individual observers was then used. Interrater agreement for each score was evaluated by calculating the Fleiss kappa coefficient (27) . The results indicated that there was no significant interobserver variation (data not shown).
For the OARSI score, measurements of histopathologic changes in the tibial and femoral surfaces were combined as 1 value (scale 0-6, where 0 = normal cartilage, 0.5 = loss of proteoglycan stain without cartilage damage, 1 = mild superficial fibrillation, 2 = fibrillation and/or clefting extending below the superficial zone, 3 = mild (<25%) loss of cartilage, 4 = moderate (25-50%) loss of cartilage, 5 = severe (50-75%) loss of noncalcified cartilage, and 6 = eburnation with >75% loss of cartilage). For the synovitis score, a subjective scoring system on a scale of 0-2 was used, in which 0 = synovial lining that has 2-3 cell layers or a thickness of <10 μm (normal), 1 = synovial thickening with 5-10 cell layers or a thickness of 10-20 μm, and 2 = severe thickening of the synovium with >10 cell layers or a thickness of >20 μm. For enumeration of osteophytes, the number of osteophytes protruding from the tibial or femoral surface to the joint space was counted.
Areas of the joint tissue that were F4/80+ (pan-macrophages), F4/80+iNOS+ (M1 macrophages), F4/80+CD206+ (M2 macrophages), or PDPN+ (lymphatic vessels) were analyzed with ImageProPlus software. The synovial area was segmented manually into regions of interest. The positive staining area was calculated as the ratio of positive staining pixels to total pixels (green pixels for pan-macrophages, and yellow pixels for M1 or M2 macrophages).
LECs. The mouse LEC line was provided by Dr. S. Ran (Southern Illinois University School of Medicine, Springfield, IL). This mouse LEC line was generated from benign lymphangiomas induced with Freund's complete adjuvant (28) . Primary LECs were isolated from the synovium and surrounding soft tissues of mouse knee joints using a previously described method (illustrated in Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40696/abstract) (29) . In brief, knee joints comprising the whole tibia and femur were digested with 1 mg/ml type I collagenase. Cells isolated from the joints were incubated with phycoerythrin (PE)-conjugated anti-mouse PDPN antibodies (BioLegend), and then resuspended in anti-PE microbeads (Miltenyi Biotec) and loaded onto an MS Column. PDPN+ cells were eluted with 1 ml MACSQuant buffer.
For characterization, the cells were stained with PEconjugated anti-mouse PDPN antibodies combined with biotin-conjugated anti-mouse lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1; eBioscience) antibodies or goat anti-mouse VEGFR-3 antibodies (R&D Systems), followed by Texas Redconjugated streptavidin (BD Biosciences) or Alexa Fluor 488-conjugated anti-goat antibodies. Cells were subjected to flow cytometry (LSRII 12-color; BD Biosciences). Results were analyzed using FlowJo software (version 7). We referred to these PDPN+ cells as synovial LECs.
RNA sequencing, pathway analysis, and real-time quantitative PCR (qPCR). Total RNA was extracted from the mouse knee joints using an RNeasy Mini kit, following the manufacturer's protocol (Qiagen). RNA-sequencing analysis was performed with an Illumina HiSeq2500 high-throughput DNA sequencer. More than 1,000 genes that were differentially expressed between posttraumatic OA mouse LECs and sham-operated mouse LECs (fold change ≥1.5 or ≤0.75) were identified. Data from the mice with posttraumatic knee OA and their counterpart controls were independently analyzed by Ingenuity Pathway Analysis (IPA) (Qiagen). IPA analyses focused on canonical pathways, biologic functions, and diseases. Realtime qPCR was performed using iQ SYBR Green Supermix and an iCycler PCR machine (a list of the sequence-specific primers used is shown in Supplementary Table 1, available Cell cultures. Generation of M1 and M2 macrophages. Bone marrow (BM) cells were isolated from wild-type (WT) mouse tibiae and femora and cultured with macrophage colony-stimulating factor for 3 days, to generate BM-derived macrophages (BMMs). M1 macrophages were induced from the BMMs using 20 ng/ml interleukin-1 (IL-1), and M2 macrophages were induced using 20 ng/ml IL-4. The phenotypes of the M1 and M2 macrophages were confirmed by immunostaining for F4/80+iNOS+ M1 macrophages and F4/80+CD206+ M2 macrophages, as described previously (30) Evaluation of the effect of macrophage-conditioned medium on LECs. Conditioned medium was collected from M1 or M2 macrophages. LECs from a murine LEC cell line were treated with 10%, 20%, or 40% macrophage-conditioned medium. Expression of inflammatory genes in the LECs was then examined by qPCR.
Evaluation of the effect of BTZ on M1 and M2 macrophages. M1 and M2 macrophages were treated with BTZ. The expression of effector genes by the M1 and M2 macrophages was determined by qPCR.
Evaluation of the effect of BTZ on M1 macrophage-mediated LEC inflammatory gene expression. BMMs on coverslips were induced to obtain the M1 macrophage subset. M1 macrophages were treated with BTZ or phosphate buffered saline (PBS) as a control. LECs were separately cultured on plastic dishes. Coverslips with BTZ-or PBS-pretreated M1 macrophages were transferred to the LEC culture dishes, and the cells were cocultured and then removed from the dishes. Expression of inflammatory genes by the LECs that were left on the plastic dishes was examined by qPCR.
Evaluation of the effect of BTZ on LECs. LECs were treated with BTZ or PBS. Expression of inflammatory genes by the treated LECs was assessed by qPCR.
Western blot analysis. BTZ was injected IA into the right knee joint of mice, while the left knee joint received vehicle control. The mice were killed 4 hours later. Synovial tissue and femoral cortical bone samples were harvested from the knee joints after removal of the BM. Proteins were extracted using ubiquitination lysis buffer. Total ubiquitinated proteins were determined by Western blotting using an anti-ubiquitin antibody (Santa Cruz Biotechnology), with β-actin used as a loading control.
Statistical analysis.
All experiments were performed at least twice, with each yielding similar results. Data are presented as the mean ± SD. Student's unpaired t-test was used to compare 2 groups. One-way analysis of variance followed by Tukey's post hoc test was used to compare more than 2 groups. An X-Y linear regression test was used for determination of any correlation between ICG clearance and OARSI score. P values less than or equal to 0.05 were considered significant.
RESULTS
Worsening of experimental posttraumatic knee OA following neutralizing antibody blockade of lymphangiogenesis. To investigate the cause-effect relationship between the synovial lymphatic system and posttraumatic knee OA, we used a VEGFR-3 neutralizing antibody to block lymphangiogenesis (20) in the joints of mice with MLI-induced posttraumatic knee OA. Three groups of mice (n = 10 mice per group) were used, including IgG-treated sham-operated mice, IgG-treated mice with posttraumatic knee OA, and VEGFR-3 antibody-treated mice with posttraumatic knee OA. The treatment (administered IP) was started on day 3 postsurgery and given 3 times per week for 6 weeks. Synovial lymphatic drainage and joint tissue damage (5) were then assessed ( Figure 1A) .
Knees from IgG-treated mice with MLI-induced OA had a lower percentage of ICG clearance (indicative of the extent of synovial lymphatic drainage) compared to IgG-treated shamoperated mice, and the ICG clearance became significantly worse in VEGFR-3 antibody-treated mice ( Figure 1B) . Results of histology showed that the MLI procedure caused cartilage loss and fibrillation in the knee joints, both of which were more severe in VEGFR-3 antibody-treated mice.
Morphometric analysis revealed higher OARSI scores, synovitis scores, and osteophyte formation in IgG-treated MLIoperated mouse knee joints than in IgG-treated sham-operated mouse knee joints, and all 3 parameters were worse in the VEG-FR-3 antibody-treated knee joints of mice with MLI-induced OA (Figures 1C-E) . There was a strong correlation between the percentage of ICG clearance and the OARSI score (R 2 = 0.7645; P < 0.001) ( Figure 1F ). These data indicate that blocking lymphangiogenesis reduces lymphatic drainage and accelerates tissue damage in the knee joints of mice with posttraumatic OA, and that the synovial lymphatic system may play an active role in the progression of posttraumatic knee OA.
Inflammatory phenotype of primary LECs from the synovium of mice with posttraumatic knee OA. Lymphatic vessels are localized in the synovium and soft tissues, mainly around the joint capsule, ligaments, fat pads, and mus- The results of flow cytometric analysis (n = 6 mice) revealed that 80% of PDPN+ cells expressed VEGFR-3, a commonly used specific LEC marker (31) , and 14% of them expressed LYVE-1, another LEC marker that is known to be expressed by a portion of LECs (32) (33) (34) (Figure 2A) .
RNA sequencing of the synovial LECs from sham-operated mouse joints (n = 5) and posttraumatic knee OA mouse joints (n = 4) revealed ~1,000 differentially expressed genes. IPA analysis indicated that these differentially expressed genes are involved in 12 dysregulated pathways, 9 of which contain an NF-κB signaling signature ( Figure 2B ).
Since NF-κB regulates expression of a variety of proinflammatory genes, we examined expression levels of the genes for IL-1, TNF, endothelial nitric oxide synthase (eNOS), and iNOS in synovial LECs from a separate set of mice that received either MLI or sham surgery (n = 5 mice per group). We included the gene for MMP-13 in this panel because it plays a critical role in cartilage degeneration in posttraumatic knee OA. OA synovial LECs had markedly increased expression of inflammatory genes (mean ± SD fold change over sham, 10.58 ± 1.16 for Il1, 39.05 ± 10.35 for Tnf, 16.34 ± 0.78 for eNOS, and 13.78 ± 4.87 for iNOS), while the increase in Mmp13 gene expression was moderate (fold change over sham, 4.45 ± 0.44) (Figure 2C) . These data suggest that LECs in the synovium of mice with experimental posttraumatic knee OA express high levels of inflammatory genes, a process we refer to herein as LEC inflammation. Association of experimental posttraumatic knee OA with increased numbers of M1 macrophages. We searched potential cellular mechanisms for the LEC inflammation in posttraumatic knee OA by examining cell populations by flow cytometry in the posttraumatic knee OA mouse joints compared to sham-operated mouse knee joints. The synovium of mice with posttraumatic knee OA had a significant increase in CD3+ T cells and F4/80+ macrophages ( Figure 3A) . In subsequent experiments, we focused on macrophages, since they are present in high numbers in knee OA and have a known role both in OA (12) and in chronic inflammation.
Macrophages are classified into inflammatory M1 or antiinflammatory M2 subsets (10) . Using the F4/80+CD86+/ CD36− phenotype to define the M1 macrophage subset, and F4/80+CD86−CD36+ to indicate the M2 macrophage subset, we found that synovial cells from mice with posttraumatic knee OA contained more M1 macrophages, but not M2 macrophages, compared to synovial cells from sham-operated mice ( Figure 3B ). 
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Immunostaining confirmed a markedly increased total of F4/80+ and F4/80+iNOS+ M1 macrophages, but not F4/80+CD206+ M2 macrophages, in OA mouse synovium compared to sham-operated mouse synovium (Figures 3C and D) . Based on these data, we hypothesized that in syno vium affected by posttraumatic knee OA, development of LEC inflammation can be attributed to the presence of M1 macro phages, which leads to reduced synovial lymphatic drainage and the progression of tissue damage. This process in the mouse posttraumatic OA model could be attenuated by IA administration of the proteasome inhibitor BTZ ( Figure 3E ).
M1 macrophage promotion of LEC inflammatory factors, and blockade by proteasome inhibitor BTZ.
To test whether M1 macrophages affect LECs in posttraumatic knee OA synovium, as proposed in Figure 3E , the potential spatial relationship between lymphatic vessels and macrophage subsets was examined by immunostaining thick sections of the mouse synovial tissue with antibodies for M1 macrophages, M2 macrophages, and LECs. Analysis of 3-D images of the tissue (n = 4 mice) revealed numerous lymphatic vessels surrounded by M1 macrophages, but not M2 macrophages (Figures 4A and B) .
LECs (a mouse LEC line) were treated with conditioned medium from BMMs, M1 macrophages, or M2 macrophages, and expression of inflammatory genes by LECs was examined. Compared to BMM-conditioned medium, M1 macrophageconditioned medium increased Il1 and iNOS levels significantly, but the effect on Tnf and Mmp13 levels was minimal. In contrast, M2 macrophage-conditioned medium decreased the expression of all of these genes ( Figure 5A ).
BTZ, a proteasome inhibitor that has been used in clinical applications, inhibits inflammation by preventing proteasomal degradation of the negative regulators of NF-κB (14) . We found that treatment with BTZ decreased M1 effector gene expression in M1 macrophages, but had no effect on M2 effector gene expression in M2 macrophages ( Figure 5B) .
Similar to the effects of M1 macrophage-conditioned medium, M1 macrophages increased inflammatory gene expression by LECs when the M1 macrophages were cocultured with LECs together. This was abolished when M1 macrophages were pretreated with BTZ ( Figure 5C ). Impressively, BTZ did not inhibit IL-1-induced inflammatory gene expression if it was added directly to LECs alone ( Figure 5D ). These data suggest that BTZ inhibits the effects of M1 macrophages on LEC inflammation by mainly modulating M1 macrophage activity, without directly affecting LECs.
Effects of BTZ in reducing inflammatory gene expression by LECs, attenuating joint tissue damage, and improving synovial lymphatic function in experimental posttraumatic knee OA. BTZ is a drug for treating multiple myeloma. It is given to patients by intravenous or subcutaneous administration. We used IA injection of BTZ into the mouse knees because this route of administration could act mainly within the joints at a high local concentration. We demonstrated that BTZ, at a dose of 0.25 mg/kg, is optimal to inhibit proteasomal degradation of ubiquitinated proteins in mouse synovial tissue ( Figure 6A ). Figure 5 . M1 macrophages promote expression of inflammatory genes by lymphatic endothelial cells (LECs), and these effects are inhibited by treatment with bortezomib (BTZ). A, Wild-type bone marrow-derived macrophages (BMMs) were treated with interleukin-1 (IL-1) or IL-4 to induce M1 or M2 macrophages, respectively. Cells were cultured for 24 hours to generate conditioned medium (CM). LECs from a murine LEC cell line were left untreated (control [Ctl]) or treated with different concentrations of M1-or M2-conditioned medium for 24 hours. Expression of inflammatory genes in LECs was determined by quantitative polymerase chain reaction (qPCR). Results are presented as the mean ± SD fold change relative to controls (set as 1.0) (n = 3 samples per group). * = P < 0.05 by analysis of variance. B, M1 or M2 macrophages were treated with phosphate buffered saline (PBS) or BTZ for 8 hours. Expression of M1 or M2 macrophage effector genes was examined by qPCR. Results are presented as the mean ± SD fold change relative to controls (set as 1.0) (n = 3 samples per group). C, M1 macrophages were pretreated with PBS or BTZ for 8 hours, and then cocultured with LECs for 24 hours. Expression of inflammatory genes by LECs was determined by qPCR. Results are presented as the mean ± SD fold change relative to controls (set as 1.0) (n = 4 samples per group). In B and C, * = P < 0.05 by Student's unpaired t-test. D, LECs were treated with PBS or BTZ for 8 hours. Expression of inflammatory genes was determined by qPCR. Results are presented as the mean ± SD fold change relative to controls (set as 1.0) (n = 3 samples per group).
An intervention protocol was used, with treatment starting at 4 weeks post-MLI. Before the treatment, we performed knee ultrasound to obtain synovial volume (21,22) , and we then randomized the mice into either the BTZ treatment group (n = 10 mice) or the vehicle control group (n = 8 mice), based on their synovial volume. Mice received a weekly injection for 7 weeks. Before termination, the mice were subjected to knee ultrasound, followed by NIR-ICG examination. The knees were harvested for histology ( Figure 6B ). Ultrasound imaging showed increased synovial volume in the vehicle-treated knee joints, with a mean ± SD fold increase of 1.95 ± 0.35. In contrast, the increase in synovial volume was much lower in BTZ-treated mouse knee joints (fold increase 0.48 ± 0.28) (Figures 6C and D) .
NIR-ICG lymphatic imaging revealed that vehicle-treated joints had significantly reduced ICG clearance (mean ± SD 48 ± 9%), which was restored by BTZ treatment to an ICG clearance of 65 ± 6% (Figures 6E and F) . The results of histologic analyses revealed that OARSI scores, synovitis scores, and osteophyte numbers were decreased in BTZ-treated mouse joints compared to controls (Figures 6G-J) .
To determine whether BTZ reduces LEC inflammation, we treated MLI-operated and sham-operated mice with IA administration of BTZ or vehicle control, and compared the expression levels of inflammatory genes by synovial LECs among the groups (vehicle-and BTZ-treated sham-operated mice versus vehicle-and BTZ-treated mice with MLI-induced posttraumatic knee OA). Treatment with BTZ had no effect on LECs from sham-operated joints, but it significantly reduced the gene expression levels of Il1, Tnf, iNOS, and Mmp13 in LECs from MLI-operated joints with posttraumatic knee OA ( Figure 6K ). These data indicate that BTZ attenuates joint tissue damage and LEC inflammation and improves synovial lymphatic drainage in mice with experimental posttraumatic knee OA.
DISCUSSION
OA is associated with high levels of catabolic factors and inflammatory cells in the joint space and the soft tissues surrounding the joint, and yet the mechanisms responsible for clearance of these factors have not been well studied. Our previous study showed that lymphatic drainage is reduced in the joints of mice with MLI-induced posttraumatic knee OA, as observed following IA administration of the NIR dye ICG (5), suggesting that there is an association between synovial lymphatic drainage and posttraumatic knee OA. However, we do not know why lymphatic drainage is reduced or whether lymphatic vessel dysfunction is a sole consequence of inflammation, or if the synovial lymphatics system plays an active role in the pathogenesis of posttraumatic knee OA. In this study, we used mice with MLI-induced experimental posttraumatic knee OA and demonstrated that blockage of lymphatic function in the OA synovium resulted in increased joint tissue damage, high expression levels of inflammatory genes by OA synovial LECs, and increased numbers of macrophages with an M1 phenotype, which further promoted the expression of inflammatory genes by LECs. In addition, IA administration of BTZ decreased cartilage loss, attenuated LEC inflammation, and improved lymphatic drainage in the posttraumatic OA knee joints. Thus, BTZ may provide a new therapy for posttraumatic knee OA, as supported by our findings suggesting that BTZ could improve synovial lymphatic function and protect against progressive joint degeneration in this disease.
Lymphangiogenesis requires the presence of the transcription factor Prox1 and the growth factor VEGF-C/VEGFR-3 signaling pathway (35, 36) . The VEGFR-3 neutralizing antibody has been used to investigate the effect of lymphatic blockage on the disease process and treatment in numerous preclinical studies, including our own study (20) . Herein, we demonstrated that VEGFR-3 blockade exacerbates tissue damage and reduces synovial lymphatic drainage in mouse knee joints with MLI-induced posttraumatic OA (Figure 1) . Thus, although our study cannot prove that lymphatic dysfunction leads to development of OA (because we treated mice that had already received MLI surgery), we demonstrated, for the first time, a negative association between lymphatic vessel function and joint injury in a mouse model of experimental OA. This makes sense, because our preliminary data previously demonstrated that MMP-13 protein is removed from the joints into the draining lymph nodes of mice with posttraumatic knee OA (data not shown).
The VEGFR-3 neutralizing antibody was given by IP injection. It may affect lymphatics systemically. This is unlikely, however, because this antibody mainly blocks newly formed lymphatic vessels, such as in tumor-induced (27) and inflammation-induced (20) lymphangiogenesis in mice. We did not find swelling or increased body weight in VEGFR-3 antibody-treated mice. In the future, we could damage lymphatic vessels locally using an ultrasound contrast agent, as has been previously described (37) , and then examine its effect on the pathogenesis of OA and the clearance of catabolic factors.
Inflammation stimulates local lymphangiogenesis, but lymphatic vessels in inflamed areas do not function sufficiently and have slower lymph flow (24) . Numerous lymphatic vessels are observed in the synovium of mice with MLI-induced posttraumatic knee OA, but these vessels have an impaired capacity to remove IA-injected ICG. Synovial LECs from these mice expressed high levels of iNOS (Figure 2) , a phenotype similar to that found in LECs from TNF-Tg mice with RA (7). Lymph flow is controlled by active and passive forces placed on collecting lymphatic vessels via lymphatic muscle cells (38) . Alternating contraction and relaxation of lymphatic muscle cells propels the lymph to draining lymph nodes and eventually to the venous circulation. Inducible NOS relaxes lymphatic muscle cells by producing an excess of nitric oxide. Thus, LECs from knee joints with posttraumatic OA may directly affect muscle cells by reducing their contractile function.
Another important finding of our study is that macrophages with the M1 phenotype promote expression of inflammatory factors by LECs ( Figure 5 ). The contribution of macrophages or myeloid cells to lymphangiogenesis has been widely investigated (39) (40) (41) . Macrophages produce factors, such as VEGF-C, to promote lymphangiogenesis (42) . Depletion of macrophages ablates the prolymphangiogenesis effect (43) . Macrophages may also function as precursors for lymphatic vessels, although this hypothesis has been challenged (44-46).
Macrophages are generally classified as proinflammatory M1 macrophages or antiinflammatory M2 macrophages. M2 macrophages are proangiogenic and prolymphangiogenic (11) in tumorigenesis. However, in age-related atherosclerosis, M1 macrophages, but not M2 macrophages, exacerbate atherosclerotic lesions (47) , suggesting that M1 macrophages mediate tissue damage in the context of chronic inflammation. Zhang et al reported that skin macrophages have a predominant M1 phenotype in Cox2 −/− mice fed with a high-salt diet. This was associated with decreased mature lymphatic ducts, dilated lymphatic vessels, and decreased lymphatic flow and lymphatic clearance (48, 49) . Our findings reveal another function for M1 macrophages-involving promotion of LECs to produce inflammatory factors via soluble factors present in conditioned medium. Currently, we do not know the identity of these soluble factors, but IL-1 and TNF, which are highly expressed by M1 macrophages, may be involved. Herein, we used cells that were induced in vitro to M1 and M2 activation states. However, it has been recognized for many years that these 2 states inadequately describe the complexity of macrophage responses within in vivo physiologic or pathologic conditions. Thus, more experiments, such as transcriptomic and systems biology analyses, are needed to further delineate the involvement of macrophage subsets in OA synovium.
The pathogenesis of OA involves multiple inflammatory pathways, and an agent that targets a single pathway, such as anti-IL-1 or anti-TNF drugs, may not be very effective (50, 51) . BTZ affects the ubiquitin-proteasome pathway that controls many inflammatory signaling proteins. Thus, BTZ may be more effective at inhibiting inflammation. However, our study has several limitations. First, joints contain many cell types. We do not have evidence to indicate a direct effect of BTZ on LECs or other cell types within the joint. We might be able to use a targeted approach by linking BTZ with anti-PDPN antibodies to deliver BTZ to LECs.
Second, we only examined 1 regimen for BTZ treatment, e.g., 4 weeks post-MLI and once a week administration. It is possible that other regimens may have better effects, such as giving the drug at an earlier stage or decreasing frequency.
Finally, we used a mouse model of experimental posttraumatic knee OA. Whether BTZ has an effect on other forms of OA, such as on age-related OA, requires additional study.
In summary, we used a combination of imaging, cell biology, and morphology in an experimental mouse model of posttraumatic knee OA and found that blockage of lymphangiogenesis accelerates joint tissue damage. Primary LECs isolated from the synovium of OA joints have an inflammatory phenotype, which is accompanied by a high number of macrophages that express M1 markers. In vitro, M1 macrophages promote production of inflammatory factors by LECs, an effect that is prevented by the proteasome inhibitor BTZ. Treatment with BTZ attenuates cartilage loss and expression of inflammatory factors by LECs, and improves lymphatic drainage in OA joints. These findings suggest a possible cellular mechanism for impaired synovial lymphatic function and a therapeutic potential of BTZ in the joints of subjects with posttraumatic knee OA.
